Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 8/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cifenline SCHEMBL23712274 | 1.00 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL23712302 | 1.00 | CACNA1F (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL121044 | 0.89 | CACNA1F (0.79) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL29387230 | 0.89 | CACNA1F (0.79) | CACNA1FARPDE4ASCN1ASCN4A | |
| Cifenline SCHEMBL28086532 | 0.74 | CACNA1F (0.55) | CACNA1FARPDE4ASCN1ASCN4A | |
| SCHEMBL5998298 | 0.68 | KDM1A (0.57) | CACNA1FARPDE4ASCN1ASCN4A | |
| Biphenyl SCHEMBL27968805 | 0.67 | NISCH (0.58) | CACNA1FARPDE4ASCN1ASCN4A | |
| SCHEMBL23712311 | 0.67 | CACNA1F (0.50) | CACNA1FARPDE4ASCN1ASCN4A | |
| SCHEMBL17886752 | 0.66 | NISCH (1.00) | CACNA1FARPDE4ASCN1ASCN4A | |
| SCHEMBL17886835 | 0.66 | NISCH (1.00) | CACNA1FARPDE4ASCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CELLTRION, INC. (KR) | 2026-01-27 | — | — | US | claimed |
| US-12419863-B2 | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | CELLTRION INC. (KR) | 2025-09-23 | — | — | US | claimed |
| EP-3485876-B1 | ORAL PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING PARTICULATE FORMULATION COMPRISING COMPOSITION | SUNSHO PHARMACEUTICAL CO LTD (JP) | 2023-11-22 | — | — | EP | claimed |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | CELLTRION, INC. (KR) | 2023-06-22 | — | — | US | claimed |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | CELLTRION, INC. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4140482-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | Celltrion, Inc. (KR) | 2023-03-01 | — | — | EP | claimed |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CELLTRION INC. (KR) | 2023-02-09 | — | — | US | claimed |
| EP-4079297-A1 | PHARMACEUTICAL FORMULATION COMPRISING CIBENZOLINE OR SALT THEREOF | Celltrion, Inc. (KR) | 2022-10-26 | — | — | EP | claimed |
| EP-3618813-B1 | IMPROVED EXTENDED RELEASE HIGHLY LOADED DRUG COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2022-07-06 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6645524-B2 | Capsules housing compressed tablets or drug-containing beads, for administering isomers of solatol and other antiarrhythmics/adrenergic blocking agents | PIERCE MANAGEMENT LLC | 2003-11-11 | — | — | US | claimed |
| EP-1311247-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS FOR PULSATILE DELIVERY OF AN ANTIARRHYTHMIC AGENT | Peirce Management, Llc (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020098232-A1 | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent | COLLEGIUM PHARMACEUTICAL, INC. | 2002-07-25 | — | — | US | claimed |
| WO-2002013794-A1 | ORAL PHARMACEUTICAL DOSAGE FORMS FOR PULSATILE DELIVERY OF AN ANTIARRHYTHMIC AGENT | PEIRCE MANAGEMENT, LLC (US) | 2002-02-21 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419863-B2 | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | CPT1B, TNNT2, TNNC1 | CACNA1F 233/4885AR 2149/4885PDE4A 2438/4885 |
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | CACNA1F 292/4885AR 3630/4885PDE4A 3415/4885 |
| US-20230122169-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | SDHA, SDHB, ALDH5A1 | CACNA1F 386/4885AR 1072/4885PDE4A 1773/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | CACNA1F 2/4885AR 3339/4885PDE4A 898/4885 |
| US-20230040902-A1 | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | CEL, SLC6A12, SLC6A1 | CACNA1F 130/4885AR 3876/4885PDE4A 574/4885 |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | ATP2A2, CPT1B, TNNT2 | CACNA1F 159/4885AR 2850/4885PDE4A 2140/4885 |
| US-12533343-B2 | Method for preparing (−)-cibenzoline succinate | CIP2A, CACNA1A, SDHA | CACNA1F 32/4885AR 2897/4885PDE4A 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.